Superworth

Amgen EV/EBIT AMGN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2010.

Today, Nov 3, 2026
25.8×
10-year median
16.9×
Against its 10-year history
89th
percentile: 0 is its lowest day, 100 its highest
10-year range
10.5× to 32.8×
Peer median
27.5×

Amgen's EV/EBIT is 25.8× as of Nov 3, 2026.

That is above its ten-year median of 16.9×, higher than on 89% of days in the last ten years.

Over that time it ranged from 10.5× in May 2019 to 32.8× in Sep 2024.

The median for 8 large drugmakers of a similar size is 27.5×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far25.8×20.9×26.7×
202523.8×21.8×30.4×
202426.9×20.3×32.8×
202320.1×14.9×20.1×
202216.4×15.1×18.2×
202117.1×15.6×18.9×
202017.0×13.6×18.6×
201915.2×10.5×15.3×
201812.1×11.3×13.6×
201711.8×11.0×13.3×
201611.4×10.6×14.5×
201514.9×13.8×20.0×
201420.5×15.8×21.3×
201315.9×10.0×16.3×
201210.3×10.3×13.6×
201112.5×7.6×12.5×
201010.5×7.7×10.9×

Against its peers

Companies in Drug Manufacturers - General nearest Amgen's size, closest first, today.

CompanyEV/EBIT
AMGNAmgen25.8×
GILDGilead Sciences24.6×
PFEPfizer14.7×
MRKMerckn/m
BMYBristol-Myers Squibbn/m
ABBVAbbVie27.5×
JNJJohnson & Johnsonn/m
LLYEli Lilly and35.1×
BIIBBiogen39.2×
Peer median27.5×

Where Amgen ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Amgen

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.